How to clear the toxic tau protein that can lead to Alzheimer's and related diseases

How to clear the toxic tau protein that can lead to Alzheimer's and related diseases

The neurotransmitter glutamate is essential for regulating everything from mood to memory, but it can also encourage a toxic buildup of protein, which can contribute to Alzheimer's and related diseases. Scientists now describe a new approach for counteracting these devastating and often fatal neurodegenerative effects. Researchers made their discovery by studying lab mice as well as human brain 'organoids,' which are rudimentary brain-like struc…

Alzheimer's treatment maker Eisai's shares sink on slow U.S. sales

TOKYO -- Japanese drugmaker Eisai's share price is hovering around a 10-year low of 4,300 yen, weighed down by poor U.S. sales of its much-touted Alzh

Alzheimer's treatment may lie in the brain's own cleanup crew: Harnessing microglia to clear plaques

For more than three decades, scientists have been racing to stop Alzheimer's disease by removing amyloid beta plaques—sticky clumps of toxic protein that accumulate in the brain.

One of the Six Isoforms of Tau Protein is Responsible for the Harms Done to Neurons

Tau protein becomes phosphorylated and aggregates into neurofibrillary tangles in the aging brain. This harms neurons, and along with inflammation is the dominant pathology in later stages of Alzheimer's disease and other tauopathies. Researchers here engineer neurons to harbor each of the six possible tau isoforms, one by one, and demonstrate that only one of those six different isoforms of tau is a cause of pathology. It remains to be seen as …

Amyloid-beta Immunization Promotes Microglial Response to Alzheimer’s Disease

In a breakthrough for Alzheimer’s disease (AD) research, scientists from Northwestern University Feinberg School of Medicine have decoded the complex role of microglia, the brain’s immune cells, in clearing amyloid-beta (Aβ) plaques—a key pathology in AD. Leveraging advanced spatial proteogenomics and single-cell analysis, the Nature Medicine study reveals how treatments like the monoclonal antibody lecanemab and the AN1792 vaccine influence mic…

Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding

The National Institute for Health and Care Excellence (NICE) has reaffirmed its stance against recommending Alzheimer’s treatments donanemab and lecanemab for NHS use, citing insufficient cost-effectiveness. Despite additional evidence submitted by manufacturers, the independent appraisal…